Cambridge Healthtech Institute (CHI) announced the publication of a new book-length report, Cancer Immunotherapy: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies, by Allan B. Haberman, Ph.D.
This report focuses on the three principal types of therapeutics that have become the major focuses of research and development in immuno-oncology in recent years:
- Checkpoint inhibitors
- Therapeutic anticancer vaccines
- Adoptive cellular immunotherapy
The discussions of these three types of therapeutics are coupled with an in-depth introduction and history as well as data for market outlook.
Also featured are three expert interviews and a survey of individuals working in immuno-oncology R&D, which focuses on market outlook, and portrays industry opinions and perspectives.
The report is designed to enable readers to understand current and future developments in immuno-oncology. It is also designed to inform the decisions of leaders in companies and in academic groups that are working in areas that relate to cancer R&D and treatment.
For more information on the report, or to order it, see the CHI Insight Pharma Reports website.
September 9, 2014
Cancer Immunotherapy: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies
Alan Haberman holds a Ph.D. in biochemistry and molecular biology from Harvard University and has an extensive background in the pharmaceutical and biotechnology industry.
More on the author.
*Report is available for single user, multi-user, single-site, multi-site or for global use.